RecruitingNCT05112614

Role of Gut Microbiome in Cancer Therapy

Sponsor

Mayo Clinic

Enrollment

3,000 participants

Start Date

Sep 11, 2019

Study Type

OBSERVATIONAL

Conditions

Malignant Solid Neoplasm Hematopoietic and Lymphoid Cell Neoplasm

Summary

This study examines how gut microbiome can affect cancer therapy in cancer patients undergoing cancer therapy or stem cell transplant. The human microbiome affects the way some cancer drugs are metabolized in the human body. Information from this study may help doctors improve the way cancer treatment is delivered, and increase its effectiveness and success.

Eligibility

Min Age: 18 YearsMax Age: 99 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a procedure called Biospecimen Collection and Electronic Health Record Review for people with hematopoietic and lymphoid cell neoplasm and malignant solid neoplasm. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 18 Years to 99 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREBiospecimen Collection

Undergo collection of blood and stool samples

OTHERElectronic Health Record Review

Review of medical records

Locations(3)

Mayo Clinic in Arizona

Scottsdale, Arizona, United States

Mayo Clinic in Florida

Jacksonville, Florida, United States

Mayo Clinic in Rochester

Rochester, Minnesota, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05112614

Related Trials

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

NCT06126276188 locations

Kinetic Analysis of Immune Cells in Blood and Chronic Graft-Versus-Host Disease-Affected Tissues After Allogeneic Hematopoietic Cell Transplantation

NCT072355011 location

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

NCT06513962205 locations

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

NCT050923731 location

Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients

NCT047125391 location